He grouped a list of several US stocks into four compartments.
The first compartment includes stocks that sold in 2020, but are expected to rebound as people “get back to normal”. The second compartment is made up of stocks which seem to have acquired a competitive advantage but which need their markets to reopen in order to capitalize.
The third are those expected to rebound when global growth picks up. And the fourth bucket is the actions that should do well in the long term but remain fragile in the short term, even if a vaccine is approved.
“While we have no opinion on when a vaccine will be approved for the virus, in this context of potential catalysts to come, we are looking at our US GIR coverage universe to identify a relatively short list of 19 stocks that, according to our analysts, could outperform once the vaccine is approved, ”wrote Chris Hussey, analyst at Goldman.